Bibliographie (2530)
A large observational study suggests eating a plant-rich diet could reduce the risk of developing severe COVID-19.
jeudi, 09 septembre 2021 12:22 Écrit par Zouhair SouissiEating a plant rich diet reduces risk of developing COVID-19 – King’s College London Original study: Diet quality and risk and severity of COVID-19: a prospective cohort study – Gut
The post A large observational study suggests eating a plant-rich diet could reduce the risk of developing severe COVID-19. appeared first on Links Medicus.
RCT: No benefit from Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis.
jeudi, 09 septembre 2021 12:22 Écrit par Zouhair SouissiCyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
The post RCT: No benefit from Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis. appeared first on Links Medicus.
AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of th
jeudi, 09 septembre 2021 12:22 Écrit par Zouhair SouissiAstraZeneca bosses warn against rush for boosters – BBC Commentary on Twitter (thread – click for more) "Moving too quickly to boost across the entire adult population will deprive us of these insights, leaving this important decision to rest on limited data," Mr Soriot and Sir Mene write.https://t.co/xTAk7yyu5G — The Sharing Scientist (@ScienceShared) September […]
The post AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”. appeared first on Links Medicus.
![[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.](/media/k2/items/cache/94cfc3c7979d9b42f14574a630002f9c_M.jpg)
[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.
jeudi, 09 septembre 2021 12:22 Écrit par Zouhair SouissiAdditional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial – medRxiv Commentary on Twitter (thread – click for more) Results of 60-person randomized trial of 3rd shot of mRNA or AZ vax in people on rituximab who didn't seroconvert after BNT-Pfizer (most) […]
The post [Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination. appeared first on Links Medicus.
![[Preprint] Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera.](/media/k2/items/cache/b4ac33f6fe81d54ed9a9247555ae868c_M.jpg)
[Preprint] Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera.
jeudi, 09 septembre 2021 12:22 Écrit par Zouhair SouissiIneffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera – bioRxiv Related: United States boosts tracking of coronavirus strains as Mu variant draws scrutiny – Science Commentary on Twitter (thread – click for more) ?Bad news on #MuVariant—Japanese scientists: "Mu variant is highly resistant to sera from convalescent & [Pfizer]-vaccinated people. […]
The post [Preprint] Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. appeared first on Links Medicus.
Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19.
mercredi, 08 septembre 2021 02:04 Écrit par Zouhair SouissiSummary: Are laboratory-made, COVID-19-specific monoclonal antibodies an effective treatment for COVID-19? – Cochrane Library Original review: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library
The post Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19. appeared first on Links Medicus.
Spread of Delta SARS-CoV-2 variant driven by a combination of immune escape and increased infectivity.
mercredi, 08 septembre 2021 02:04 Écrit par Zouhair SouissiNews release: Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity – University of Cambridge Original article: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion – Nature
The post Spread of Delta SARS-CoV-2 variant driven by a combination of immune escape and increased infectivity. appeared first on Links Medicus.
Supplement: Current Issues in Venous Thromboembolism.
mardi, 07 septembre 2021 23:42 Écrit par Zouhair SouissiHomepage: Current Issues in Venous Thromboembolism – Postgraduate Medicine Editorial: Current issues in venous thromboembolism A review of upper extremity deep vein thrombosis Outpatient treatment of emergency department patients diagnosed with venous thromboembolism Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery Prophylaxis and treatment of COVID-19 related venous thromboembolism Challenges in the diagnostic approach […]
The post Supplement: Current Issues in Venous Thromboembolism. appeared first on Links Medicus.
Isn’t it time to abandon ARDS? The COVID-19 lesson.
mardi, 07 septembre 2021 23:42 Écrit par Zouhair SouissiIsn’t it time to abandon ARDS? The COVID-19 lesson – Critical Care Commentary on Twitter #CritCare #OA #Gattinoni & #Marini: Keeping or abandoning #ARDS? ▶️ pros ▶️ conshttps://t.co/tIhusXT2S7#FOAMed #FOAMcc #BMC #COVID19 #Rx #RCT #PEEP #respiratory_failure #Personalized pic.twitter.com/M6aoiSAn3m — Critical Care (@Crit_Care) September 7, 2021
The post Isn’t it time to abandon ARDS? The COVID-19 lesson. appeared first on Links Medicus.
![[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.](/media/k2/items/cache/6b1c619be8b23a102b3cd1b7967289e5_S.jpg)
[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.
mardi, 07 septembre 2021 23:42 Écrit par Zouhair SouissiThe prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals – medRxiv Commentary on Twitter A new systematic review of over 12 million people from 54 studies at up to 8 months following Covid. >90% prevalence of IgG antibodies, reinfection 0.2% (an […]
The post [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection. appeared first on Links Medicus.
